Preliminary investigations of a new beta‐adrenoceptive receptor blocking drug, LB46, in man

Abstract

1 . Preliminary studies in man of a new beta‐adrenoceptive receptor blocking drug, dl‐4‐(2‐hydroxy‐3‐isopropylaminopropoxy)‐indole (LB46), are described. 2 . LB46, 0.5 mg by oral administration, appeared to be of similar potency to propranolol 20 mg in inhibiting isoprenaline‐induced and exercise‐induced tachycardia. 3 . In comparable beta‐receptor blocking doses LB46 did not show the negative chronotropic property possessed by propranolol.